Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 4/20 | 0.35 |
| ▸ | TERT | O14746 | 1/20 | 0.35 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.34 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.34 |
| ▸ | ANPEP | P15144 | 1/20 | 0.33 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.33 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.32 |
| ▸ | TLR2 | O60603 | 2/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.32 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13255060 | 0.82 | MEN1 (0.59) | MEN1KMT2ACA2TERTANPEP | |
| SCHEMBL9122686 | 0.82 | MEN1 (0.55) | MEN1KMT2ACA2TERTCARM1 | |
| SCHEMBL11027129 | 0.81 | — | — | |
| SCHEMBL13360298 | 0.78 | MEN1 (0.54) | MEN1KMT2ACA2TERTANPEP | |
| SCHEMBL15623806 | 0.78 | MEN1 (0.48) | MEN1KMT2ATLR2DPP7SLC15A1 | |
| SCHEMBL23610794 | 0.77 | MEN1 (0.47) | MEN1KMT2ACA2TERTSMN1; SMN2 | |
| SCHEMBL4141437 | 0.77 | MEN1 (0.47) | MEN1KMT2ACA2TERTSMN1; SMN2 | |
| SCHEMBL7397789 | 0.77 | MEN1 (0.47) | MEN1KMT2ACA2TERTSMN1; SMN2 | |
| SCHEMBL14655413 | 0.77 | MEN1 (0.53) | MEN1KMT2ACA2ANPEPTLR2 | |
| SCHEMBL9140089 | 0.76 | USP2 (0.50) | MEN1KMT2ATERTANPEPDNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220002230-A1 | COMPOUND CONTAINING DIPHENYLMETHANE STRUCTURE AND USE THEREOF | GUANGZHOU CONGEN PHARMATEC CO., LTD. (CN) | 2022-01-06 | — | — | US | disclosed |
| WO-2020186840-A1 | COMPOUND CONTAINING FLUORENE RING STRUCTURE AND APPLICATION THEREOF | 广州同隽医药科技有限公司 | 2020-09-24 | — | — | WO | disclosed |
| WO-2020155879-A1 | COMPOUND CONTAINING BENZYL STRUCTURE AND USE THEREOF | 广州同隽医药科技有限公司 | 2020-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220002230-A1 | COMPOUND CONTAINING DIPHENYLMETHANE STRUCTURE AND USE THEREOF | PEPD, VIP, DNPEP | MEN1 2547/4885KMT2A 3822/4885CA2 2533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.